Santosa Anindita, Li James Weiquan, Tan Tze Chin
Aaria Rheumatology, 6 Napier Road 08-19, Gleneagles Medical Centre, Singapore258499, Singapore.
Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Bull World Health Organ. 2025 Feb 1;103(2):136-147. doi: 10.2471/BLT.24.292168. Epub 2024 Dec 11.
To evaluate the adoption, effectiveness and cost-effectiveness of digital health interventions for rheumatic disease management.
Between 25 May 2024 and 2 June 2024, we systematically searched PubMed®, Scopus, ClinicalTrials.gov, the Global Observatory for eHealth and the World Bank Open Knowledge Repository for randomized controlled trials (RCTs) evaluating digital health interventions for rheumatic disease management. We included studies published between 2000 and 2024 that reported on adoption rates and efficacy. Two reviewers independently screened the studies, extracted data and categorized the digital interventions according to the World Health Organization's classification of digital health interventions.
Of the 455 unique records identified, 21 RCTs met the inclusion criteria. Most digital health interventions (15 studies) focused on individual-centric interventions, such as targeted communication, personal health tracking, educational tools and wearable devices. Studies in high-income countries implemented advanced, integrated digital interventions combining individual-focused approaches with health worker interventions and data services using telemedicine platforms and decision support systems. In contrast, studies in low- and middle-income countries adapted accessible technologies such as mobile messaging and telephone-based education. Many telehealth, wearable technologies and educational interventions significantly improved disease control, patient adherence, knowledge and self-efficacy. Of the five studies assessing cost-effectiveness, all found digital interventions to be cost-effective.
Digital health interventions show promise for managing rheumatic diseases. Tailoring these interventions to local infrastructure and emphasizing patient engagement are crucial for successful adoption. Future research should focus on standardizing evaluation methods, addressing digital divides and enhancing provider support and data services.
评估数字健康干预措施在风湿病管理中的采用情况、有效性和成本效益。
在2024年5月25日至2024年6月2日期间,我们系统地检索了PubMed®、Scopus、ClinicalTrials.gov、全球电子健康观察站和世界银行开放知识存储库,以查找评估数字健康干预措施在风湿病管理中的随机对照试验(RCT)。我们纳入了2000年至2024年发表的报告采用率和疗效的研究。两名评审员独立筛选研究、提取数据,并根据世界卫生组织的数字健康干预措施分类对数字干预措施进行分类。
在识别出的455条独特记录中,21项RCT符合纳入标准。大多数数字健康干预措施(15项研究)侧重于以个人为中心的干预措施,如定向沟通、个人健康跟踪、教育工具和可穿戴设备。高收入国家的研究实施了先进的综合数字干预措施,将以个人为重点的方法与卫生工作者干预措施以及使用远程医疗平台和决策支持系统的数据服务相结合。相比之下,低收入和中等收入国家的研究采用了如移动消息和电话教育等易于获取的技术。许多远程医疗、可穿戴技术和教育干预措施显著改善了疾病控制、患者依从性、知识和自我效能。在评估成本效益的五项研究中,所有研究都发现数字干预措施具有成本效益。
数字健康干预措施在管理风湿病方面显示出前景。根据当地基础设施调整这些干预措施并强调患者参与对于成功采用至关重要。未来的研究应侧重于标准化评估方法、解决数字鸿沟以及加强提供者支持和数据服务。